Sanofi and Michael J. Fox Foundation Collaborate on Potential New Treatment for Parkinson's Disease
Paris, France - Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that it has entered into a collaboration with the Michael J. Fox Foundation (MJFF) to conduct a clinical trial to assess the safety and tolerability of AVE 8112, a Sanofi PDE4 inhibitor Ė phosphodiesterase type 4 inhibitor - in patients with Parkinsonís disease (PD).
ďAVE8112 has shown promising pro-cognitive activity in preclinical models that could be of interest to the under-addressed cognitive aspects of Parkinsonís disease, an area of unmet need where a new treatment could make a tangible difference in patientsí lives,Ē said Todd Sherer, Ph.D., Chief Executive Officer of MJFF. ďGroundbreaking collaborations with like-minded partners such as Sanofi are a hallmark of the Fox Foundationís approach and help us speed scientific advances with potential to improve the treatment of Parkinsonís for patients today and in the future.Ē
Under the terms of the collaboration, MJFF will sponsor a phase I b clinical trial to assess the safety and tolerability of AVE8112 in patients with Parkinsonís disease. All data and results generated by the clinical trial will be owned by MJFF and shared with Sanofi. Further development plans will be based upon the results of the study.
ďThe Michael J. Fox Foundation has been a driving force in discovering and developing improved therapies for those living with Parkinsonís disease. Through this research collaboration, together we will be able to study Sanofiís pharmaceutical compound for a possible new treatment for PD patients around the world,Ē said Dr. Elias Zerhouni, President, Global R&D, Sanofi. ďWe hope to continue to develop relationships with private foundations like the Michael J. Fox Foundation to pool our resources and maximize the potential of our drug portfolio to address unmet medical needs.Ē
The clinical trial will be conducted at clinical sites in the United States in Baltimore, MD, and Los Angeles, CA. Patient enrollment in the study is expected to begin later this year.†
About Parkinsonís Disease
Over one million people in the US and an estimated 5 million people globally suffer from Parkinsonís disease, a neurodegenerative disorder caused by the diminished production of dopamine, a key neurotransmitter, resulting in progressive impairment of motor function including tremors, rigidity and difficulty in moving. Another symptom of PD is cognitive dysfunction, such as difficulty planning, sequencing, initiating and sustaining behavior toward a goal. Estimates vary but some studies suggest a cognitive deficit may occur in up to 80% of people with Parkinson's. While there is a drug approved for the treatment of dementia in PD, there are currently no treatments available for patients who experience less severe cognitive impairments.
Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patientsí needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
About The Michael J. Fox Foundation for Parkinsonís Research
As the worldís largest private funder of Parkinsonís research, The Michael J. Fox Foundation is dedicated to accelerating a cure for Parkinsonís disease and improved therapies for those living with the condition today. The Foundation pursues its goals through an aggressively funded, highly targeted research program coupled with active global engagement of scientists, Parkinsonís patients, business leaders, clinical trial participants, donors and volunteers. In addition to funding more than $285 million in research to date, the Foundation has fundamentally altered the trajectory of progress toward a cure. Operating at the hub of worldwide Parkinsonís research, the Foundation forges groundbreaking collaborations with industry leaders, academic scientists and government research funders; increases the flow of participants into Parkinsonís disease clinical trials with its online tool, Fox Trial Finder; promotes Parkinsonís awareness through high-profile advocacy, events and outreach; and coordinates the grassroots involvement of thousands of Team Fox members around the world. Now through December 31, 2012, all new and increased giving to The Michael J. Fox Foundation, as well as gifts from donors who have not given since 2009 or earlier, will be matched on a dollar-for-dollar basis with the $50-million Brin Wojcicki Challenge, launched by Sergey Brin and Anne Wojcicki.